Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 547-549

  Klaassen, U ^a   Wilke, H ^a   Strumberg, D ^a   Eberhardt, W ^a   Korn, M ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

1 h infusion; Breast cancer; Ovarian cancer; Paclitaxel; Phase I

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CIMETIDINE; CISPLATIN; CLEMASTINE; DEXAMETHASONE; PACLITAXEL;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; REMISSION INDUCTION;

EID: 0029947348     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00641-9     Document Type: Article

References (6)

1. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984, 25, 83-125.
2. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989, 111, 273-279.
3. Nabholtz JM, Gelmon K, Bontenbal M, et al. Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis (abstr. 42). Proc Am Soc Clin Oncol 1993, 12, 63.
4. Rowinsky EK, Donehower RC, Tucker RW. Microtubule changes and cytotoxicity in leukemic cells treated with taxol. Cancer Res 1988, 48, 4093-4100.
5. Lopes NM, Adams EG, Pitts TW, et al. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cancer cell lines. Cancer Chemother Pharmacol 1993, 32, 235-242.
6. Arbuck SG, Blaylock BA. Dose and schedule issues. In McGuire WP, Rowinsky EK, eds. Paclitaxel in Cancer Treatment. New York, Marcel Dekker, 1995.